Desk›Healthcare› Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd
BSE 539997 · NSE KPL · ISIN INE552U01010 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹3,310.25
+1.37%
BSE close, 28 August 2026
₹3,434.78 cr
1.0 cr shares · Micro cap
₹1,517.02 cr
as published
42.4× · 14.15×
EPS ₹78.10 · BV ₹233.94
503.06 / 67.35
₹ cr, as filed
17
6 selected · 35%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -11.1% |
|---|---|
| Against 52-week low | +299.4% |
| Day change | +1.37% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹78.10 |
|---|---|
| Price / earnings | 42.38× |
| Price / book | 14.15× |
| Book value — derived, price ÷ P/B | ₹233.94 |
| Return on equity | 33.38% |
| Operating margin | 25.65% |
| Net margin | 15.78% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 33.39%
- ROE as published
- 33.38%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 162.35 | 25.63 | 24.70 | 25.65% | 15.78% |
| Mar-26 · Q | 156.82 | 25.29 | 24.37 | 25.38% | 16.13% |
| FY25-26 | 503.06 | 67.35 | 64.90 | 23.91% | 13.39% |
Quarter on quarter
- Revenue, quarter on quarter
- +3.5%
- Net profit, quarter on quarter
- +1.3%
- Operating margin, quarter on quarter
- +27 bps
Disclosure profile 17 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Concall Transcript | 2 |
| Board Outcome | 1 |
| Change in Management | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 6 |
| Procedural | |
| Analyst / Investor Meet | 4 |
| AGM / EGM | 2 |
| Newspaper Publication | 2 |
| Board Meeting | 1 |
| General | 1 |
| Trading Window | 1 |
| Procedural sub-total | 11 |
| Total | 17 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
17 filings · 6 selected · busiest 2026-08-12
Filing rhythm · the twelve most recent
2026-08-102026-09-28
SelectedProcedural
Filings
17 in the window · 2 earlier on record
-
28 September 2026 ·
Closure of Trading Window
Intimation of Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
2 September 2026 ·
Change in Management
Regularization of appointment of Mr Swanith Kapoor as Director and reappointment of Mr Aditya Arora as WTD of the company
Company Update / Change in Management View filing →
-
2 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
SCRUTINIZER REPORT OF AGM E-VOTING IS ATTACHED
AGM/EGM / AGM View filing →
-
31 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 43rd Annual General Meeting attached herewith.
AGM/EGM / AGM View filing →
-
13 August 2026 ·
Newspaper Publication
Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.
Company Update / Newspaper Publication View filing →
-
12 August 2026 ·
Newspaper Publication
Newspaper Publication of Notice of 43rd Annual General Meeting.
Company Update / Newspaper Publication View filing →
-
12 August 2026 ·
Analyst / Investor Meet - Outcome
Outcome of Investors/Analysts Meeting held on August 10, 2026
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Earnings Call Transcript
Transcript of Earnings Conference Call - Q1FY27
Company Update / Earnings Call Transcript View filing →
-
12 August 2026 ·
Earnings Call Transcript
Transcript of Earnings Conference Call - Q1FY27
Company Update / Earnings Call Transcript View filing →
-
10 August 2026 ·
Investor Presentation
Investor Presentation for quarter ended June 30, 2026.
Company Update / Investor Presentation View filing →
-
10 August 2026 ·
Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations, 2015
Financial Results for Quarter Ended June 30, 2026.
Result / Financial Results View filing →
-
10 August 2026 ·
Board Meeting Outcome for Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations, 2015
Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015
Board Meeting / Outcome of Board Meeting View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for Q1 FY 2026-27
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for Q1 FY 2026-27
Company Update / Analyst / Investor Meet View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for Q1 FY 2026-27
Company Update / Analyst / Investor Meet View filing →
-
3 August 2026 ·
Board Meeting Intimation for Consideration And Approval Of Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2026.
Kwality Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Standalone and ....
Board Meeting / Board Meeting View filing →
-
24 July 2026 ·
Disclosure Under Regulation 30 Of SEBI LODR
Kwality Pharmaceuticals receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab
Company Update / General View filing →
RSS feed for Kwality Pharmaceuticals Ltd · the 50 most recent filings